About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2013 (2013), Article ID 419375, 7 pages
http://dx.doi.org/10.1155/2013/419375
Clinical Study

The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease

1Department of Gastroenterology, Tongji Hospital, Tongji University School of Medicine, Shanghai 20065, China
2Department of Gastroenterology, the Tenth People's Hospital of Shanghai, Tongji University School of Medicine, Shanghai 200072, China
3Department of Private Ward, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China
4Department of Clinic Nutrition, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Received 4 October 2012; Revised 7 January 2013; Accepted 30 January 2013

Academic Editor: Fernando A. M. Herbella

Copyright © 2013 Ying Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Gastroesophageal reflux disease is a diversity disease that affects life quality of people in the world. Due to the complicated pathogenesis and variations in clinical manifestations, there is still no true gold standard for GERD diagnosis, and it is still difficult to diagnose this disease in some patients. The proton pump inhibitor’s diagnostic test (the PPI test) is noninvasive, of low cost, tied to treatment, and widely accepted. Our aim is to evaluate the diagnostic significance of coapplying a rabeprazole test with the SF-36 for GERD in this study. Our study shows that the SF-36 in combination with the rabeprazole test can screen GERD patients and increase the sensitivity and specificity of GERD diagnosis through reference to the change in SF-36 score before and after the treatment (65 in the trial).